Mr. Peter Edwards reports
AETERNA ZENTARIS ANNOUNCES RESULTS OF 2020 ANNUAL MEETING OF SHAREHOLDERS
Aeterna Zentaris Inc. has released the results from its annual general meeting (AGM) held on May 15, 2020.
The individuals noted below were elected as Directors of the Company. The report on proxies provided by the Company's transfer agent indicated the following:
The Company would like to welcome Peter Edwards to the Board of Directors.
The Company would also like to extend its sincere thanks and best wishes to Gerard Limoges, Dr. Brent Norton, and Robin Smith Hoke who have been valued members of Aeterna's Board of Directors.
The Company also reported the re-appointment of PricewaterhouseCoopers LLP as the Company's independent auditor.
For full voting details, please see the voting results of Aeterna Zentaris on SEDAR and on EDGAR.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.